Amarin Corp Plcuk (AMRN) Equity Average (2010 - 2026)
Amarin Corp Plcuk (AMRN) posted quarterly Equity Average of $454.3 million for Q1 2026, down 5.33% YoY from $479.9 million in Q1 2025, and down 1.03% sequentially from $459.1 million in Q4 2025.
Amarin Corp Plcuk (AMRN) Equity Average (2010 - 2026) Analysis & Trends
Amarin Corp Plcuk has disclosed Equity Average across 17 years of filings, most recently posting $454.3 million for Q1 2026.
- In Q1 2026, Equity Average fell 5.33% year-over-year to $454.3 million; the TTM figure through Mar 2026 stood at $454.3 million (down 5.33% YoY), while the FY2025 annual figure was $472.7 million, down 8.94% from the prior year.
- Equity Average retreated to $454.3 million in Q1 2026, from $459.1 million in the prior quarter.
- Over the last five years, Equity Average for AMRN reached as high as $654.1 million in Q1 2022 and fell as low as $454.3 million in Q1 2026.
- The 5-year median for Equity Average is $549.0 million (2024), against an average of $540.8 million.
- Annual changes were most pronounced in 2022 — Equity Average climbed 3.65% — and 2025, when it slipped 14.72%.
- A 5-year view of Equity Average shows it stood at $591.6 million in 2022, then retreated by 6.59% to $552.6 million in 2023, then decreased by 7.93% to $508.8 million in 2024, then declined by 9.77% to $459.1 million in 2025, then dropped by 1.03% to $454.3 million in 2026.
- According to Business Quant data, Equity Average over the past three periods registered $454.3 million, $459.1 million, and $461.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 28.87 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 81.37 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | -4.96 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | - |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 49.27 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 8.92 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 23.11 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 88.29 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Amarin Corp Plcuk | 5.17 Bn | 5.00 Bn | 17.77 Mn | 454.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 454.35 Mn |
| Dec 31, 2025 | 459.09 Mn |
| Sep 30, 2025 | 461.91 Mn |
| Jun 30, 2025 | 469.31 Mn |
| Mar 31, 2025 | 479.93 Mn |
| Dec 31, 2024 | 508.78 Mn |
| Sep 30, 2024 | 541.63 Mn |
| Jun 30, 2024 | 548.91 Mn |
| Mar 31, 2024 | 549.02 Mn |
| Dec 31, 2023 | 552.62 Mn |
| Sep 30, 2023 | 561.14 Mn |
| Jun 30, 2023 | 576.96 Mn |
| Mar 31, 2023 | 590.06 Mn |
| Dec 31, 2022 | 591.58 Mn |
| Sep 30, 2022 | 583.94 Mn |
| Jun 30, 2022 | 610.58 Mn |
| Mar 31, 2022 | 654.10 Mn |
| Dec 31, 2021 | 654.80 Mn |
| Sep 30, 2021 | 643.91 Mn |
| Jun 30, 2021 | 639.97 Mn |